Empowering People to be Ambassadors of their Own Health Since 1997.


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer
Literature Review, May 2015



Relationship between CD4+CD25+ Treg and expression of HIF-1α and Ki-67 in NSCLC patients. He LY1, Li L, Guo ML, Zhang Y, Zhang HZ. Eur Rev Med Pharmacol Sci. 2015 Apr;19(8):1351-5.

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer. Blakely CM1, Pazarentzos E1, Olivas V1, et al. Cell Rep. 2015 Apr 7;11(1):98-110. doi: 10.1016/j.celrep.2015.03.012. Epub 2015 Apr 2.

Pulmonary Adenocarcinoma In Situ: Analyses of a Large Series With Reference to Smoking, Driver Mutations, and Receptor Tyrosine Kinase Pathway Activation. Sato S1, Motoi N, Hiramatsu M, et al. Am J Surg Pathol. 2015 Apr 8. [Epub ahead of print]

Molecular features and clinical outcome of lung malignancies in very young people. Catania C1, Botteri E, Barberis M, et al. Future Oncol. 2015 Apr;11(8):1211-21. doi: 10.2217/fon.15.10.

Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients. Chen X1, Chen D1, Yang S1, Ma R1, Pan Y1, Li X1, Ma S1. Cancer Cell Int. 2015 Apr 19;15:43. doi: 10.1186/s12935-015-0191-3. eCollection 2015.

Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis. Barck KH1, Bou-Reslan H1, Rastogi U1, et al. Transl Oncol. 2015 Apr;8(2):126-35. doi: 10.1016/j.tranon.2015.03.003.

Fibulin-5 inhibits Wnt/β-catenin signaling in lung cancer. Chen X1,2, Song X1, Yue W2, Chen D2, Yu J3, Yao Z1, Zhang L2. Oncotarget. 2015 Apr 2. [Epub ahead of print]




The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients. Fu S1, Liang Y2, Lin YB3, et al. PLoS One. 2015 Apr 23;10(4):e0124354. doi: 10.1371/journal.pone.0124354. eCollection 2015.

Racial Differences in Outcomes within the National Lung Screening Trial: Implications for Widespread Implementation. Tanner NT1, Gebregziabher M, Hughes Halbert C, Payne E, Egede LE, Silvestri GA. Am J Respir Crit Care Med. 2015 Apr 30. [Epub ahead of print]

Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non-Small-Cell Lung Cancer. Kitazono S1, Fujiwara Y2, Tsuta K3, et al. Clin Lung Cancer. 2015 Apr 4. pii: S1525-7304(15)00083-2. doi: 10.1016/j.cllc.2015.03.008. [Epub ahead of print]

The Role of Immunohistochemical Analysis in the Evaluation of EML4-ALK Gene Rearrangement in Lung Cancer. Sullivan HC1, Fisher KE, Hoffa AL, Wang J, Saxe D, Siddiqui MT, Cohen C. Appl Immunohistochem Mol Morphol. 2015 Apr;23(4):239-44. doi: 10.1097/PAI.0000000000000088.

Prognostic impact of vascular invasion and standardization of its evaluation in stage I non-small cell lung cancer. Hamanaka R1,2, Yokose T3, Sakuma Y4, et al. Diagn Pathol. 2015 Apr 2;10(1):17. doi: 10.1186/s13000-015-0249-5.

Thoracic staging of non-small-cell lung cancer using integrated 18F-FDG PET/MR imaging: diagnostic value of different MR sequences. Schaarschmidt B1, Buchbender C, Gomez B, et al. Eur J Nucl Med Mol Imaging. 2015 Apr 8. [Epub ahead of print]

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. Wang S1, Yu B1, Ng CC1, Mercorella B1, Selinger CI1, O’Toole SA1, Cooper WA1. Transl Lung Cancer Res. 2015 Apr;4(2):119-25. doi: 10.3978/j.issn.2218-6751.2015.01.05.

99mTc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab. Ma Q1, Min K, Wang T, Chen B, Wen Q, Wang F, Ji T, Gao S. Ann Nucl Med. 2015 Apr 25. [Epub ahead of print]


Outcomes of lobar and sublobar resections for non-small-cell lung cancer: a single-center experience. Kim D1, Ferraris VA1, Davenport D1, Saha S1. South Med J. 2015 Apr;108(4):230-4. doi: 10.14423/SMJ.0000000000000272.

Does Thoracoscopic Surgery Decrease the Morbidity of Combined Lung and Chest Wall Resection? Hennon MW1, Dexter EU1, Huang M1, et al. Ann Thorac Surg. 2015 Apr 24. pii: S0003-4975(15)00246-5. doi: 10.1016/j.athoracsur.2015.02.038. [Epub ahead of print]

Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. Falcoz PE1, Puyraveau M2, Thomas PA3, et al. Eur J Cardiothorac Surg. 2015 Apr 26. pii: ezv154. [Epub ahead of print]

Non-grasping en bloc mediastinal lymph node dissection for video-assisted thoracoscopic lung cancer surgery. Liu C1, Pu Q2, Guo C3, Xiao Z4, Mei J5, Ma L6, Zhu Y7, Liao H8, Liu L9. BMC Surg. 2015 Apr 8;15(1):38. doi: 10.1186/s12893-015-0025-1.

Comparison of stereotactic body radiation therapy for biopsy-proven versus radiographically diagnosed early-stage non-small lung cancer: a single-institution experience. Fischer-Valuck BW1, Boggs H, Katz S, Durci M, Acharya S, Rosen LR. Tumori. 2015 Apr 9;0(0):0. doi: 10.5301/tj.5000279. [Epub ahead of print]

Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer. Yu JB1, Soulos PR, Cramer LD, Decker RH, Kim AW, Gross CP. Cancer. 2015 Apr 6. doi: 10.1002/cncr.29359. [Epub ahead of print]

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer. Samson P1, Patel A1, Garrett T1, et al. Ann Thorac Surg. 2015 Apr 15. pii: S0003-4975(15)00228-3. doi: 10.1016/j.athoracsur.2015.02.022. [Epub ahead of print]

Long-Term Outcomes of Lobectomy for Non-Small Cell Lung Cancer After Definitive Radiation Treatment. Yang CF1, Meyerhoff RR2, Stephens SJ1, et al. Ann Thorac Surg. 2015 Apr 15. pii: S0003-4975(15)00215-5. doi: 10.1016/j.athoracsur.2015.01.064. [Epub ahead of print]

Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung Cancer. Bott MJ1, Patel AP1, Crabtree TD1, et al. Ann Thorac Surg. 2015 Apr 23. pii: S0003-4975(15)00241-6. doi: 10.1016/j.athoracsur.2015.02.033. [Epub ahead of print]


Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated? Sacher AG1, Le LW, Lau A, Earle CC, Leighl NB. Cancer. 2015 Apr 17. doi: 10.1002/cncr.29386. [Epub ahead of print]

Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer. Ganti AK1, Williams CD, Gajra A, Kelley MJ. Cancer. 2015 Apr 14. doi: 10.1002/cncr.29360. [Epub ahead of print]

High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial. Hoffer LJ1, Robitaille L2, Zakarian R3, et al. PLoS One. 2015 Apr 7;10(4):e0120228. doi: 10.1371/journal.pone.0120228. eCollection 2015.

Gemcitabine plus vinorelbine as the second-line treatment and beyond in elderly patients with platinum-pretreated advanced non-small cell lung cancer. Go SI1, Lee WS, Lee GW, et al. Chemotherapy. 2014;60(4):267-73. doi: 10.1159/000381636. Epub 2015 Apr 28.

A Randomized Phase III Trial of Oral S-1 plus Cisplatin versus Docetaxel plus Cisplatin in Japanese Patients with Advanced Non-small-cell Lung Cancer: TCOG0701 CATS TRIAL. Kubota K1, Sakai H2, Katakami N3, et al. Ann Oncol. 2015 Apr 23. pii: mdv190. [Epub ahead of print]


Early assessment of metabolic response by 18F-FDG PET during concomitant radiochemotherapy of non-small cell lung carcinoma is associated with survival: a retrospective single-center study. Yossi S1, Krhili S, Muratet JP, Septans AL, Campion L, Denis F. Clin Nucl Med. 2015 Apr;40(4):e215-21. doi: 10.1097/RLU.0000000000000615.

ACR Appropriateness Criteria(®) induction and adjuvant therapy for N2 non-small-cell lung cancer. Willers H1, Stinchcombe TE, Barriger RB, et al. Am J Clin Oncol. 2015 Apr;38(2):197-205. doi: 10.1097/COC.0000000000000154.

Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Zeng YD1, Liao H2, Qin T1, et al. Oncotarget. 2015 Apr 10;6(10):8366-76.

Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation? Wang TJ1, Saad S1, Qureshi YH1, et al. Neuro Oncol. 2015 Apr 24. pii: nov043. [Epub ahead of print]

Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy. Woody NM1, Stephans KL2, Marwaha G2, Djemil T2, Videtic GM2. Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):325-31. doi: 10.1016/j.ijrobp.2015.01.045. Epub 2015 Apr 1.

Imaging and dosimetric errors in 4D PET/CT-guided radiotherapy from patient-specific respiratory patterns: a dynamic motion phantom end-to-end study. Bowen SR1, Nyflot MJ, Herrmann C, et al. Phys Med Biol. 2015 May 7;60(9):3731-46. doi: 10.1088/0031-9155/60/9/3731. Epub 2015 Apr 17.




Network analysis of differentially expressed genes reveals key genes in small cell lung cancer. Tantai JC1, Pan XF, Zhao H. Eur Rev Med Pharmacol Sci. 2015 Apr;19(8):1364-72.

Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. Iwakawa R1, Kohno T2, Totoki Y3, et al. Carcinogenesis. 2015 Apr 11. pii: bgv026. [Epub ahead of print]

Lysosome-associated protein transmembrane-4β-35 is a novel independent prognostic factor in small cell lung cancer. Qiao M1, Hu G. Tumour Biol. 2015 Apr 25. [Epub ahead of print]

Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer. Matsumoto M1, Seike M2, Noro R3, et al. BMC Cancer. 2015 Apr 9;15(1):241. doi: 10.1186/s12885-015-1202-4.

The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients. Miura S1, Kaira K, Kaira R, et al. Invest New Drugs. 2015 Apr 7. [Epub ahead of print]

Increased serum carcinoembryonic antigen level can predict poor survival of patients with small cell lung cancer. Zhu H1, Guo H2, Li M1, et al. Transl Res. 2015 Apr 14. pii: S1931-5244(15)00112-7. doi: 10.1016/j.trsl.2015.04.005. [Epub ahead of print]


PA14 The legacy of cancer: why a health promoting approach is so important in palliative care. Baker N1, Armour K1, Meystre C1, Redwood S1, Dawson A1. BMJ Support Palliat Care. 2015 Apr;5 Suppl 1:A23-4. doi: 10.1136/bmjspcare-2015-000906.74.

Implementation of Supportive Care and Best Supportive Care Interventions in Clinical Trials Enrolling Patients with Cancer. Lee RT1, Ramchandran K2, Sanft T3, Von Roenn J4. Ann Oncol. 2015 Apr 28. pii: mdv207. [Epub ahead of print]

Coping with an Advanced Stage Lung Cancer Diagnosis: Patient, Caregiver, and Provider Perspectives on the Role of the Health Care System. Islam KM1, Opoku ST, Apenteng BA, et al. J Cancer Educ. 2015 Apr 23. [Epub ahead of print]

Exercise preferences, levels and quality of life in lung cancer survivors. Leach HJ1, Devonish JA, Bebb DG, Krenz KA, Culos-Reed SN. Support Care Cancer. 2015 Apr 2. [Epub ahead of print]

A week in the life of lung cancer survivors: Daily reports of stress, worry, mood, and symptoms. Aronson KR1, Wagstaff DA2, Farace E3, et al. J Health Psychol. 2015 Apr 6. pii: 1359105315574921. [Epub ahead of print]

Is There a Need for Early Palliative Care in Patients With Life-Limiting Illnesses? Interview Study With Patients About Experienced Care Needs From Diagnosis Onward. Beernaert K1, Deliens L2, Vleminck A2, et al. Am J Hosp Palliat Care. 2015 Apr 7. pii: 1049909115577352. [Epub ahead of print]

Proteomic analysis of media from lung cancer cells reveals role of 14-3-3 proteins in cachexia. McLean JB1, Moylan JS2, Horrell EM3, Andrade FH1. Front Physiol. 2015 Apr 28;6:136. doi: 10.3389/fphys.2015.00136. eCollection 2015.



Fuzheng Kang’ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial. Yang XB1, Wu WY2, Long SQ3, et al. Trials. 2015 Apr 10;16(1):146. doi: 10.1186/s13063-015-0685-2.

Japonicone A inhibits the growth of non-small cell lung cancer cells via mitochondria-mediated pathways. Du Y1, Gong J, Tian X, et al. Tumour Biol. 2015 Apr 25. [Epub ahead of print]

So-Cheong-Ryong-Tang induces apoptosis through activation of the intrinsic and extrinsic apoptosis pathways, and inhibition of the PI3K/Akt signaling pathway in non-small-cell lung cancer A549 cells. Park C1, Hong SH2, Kim GY3, Choi YH4,5. BMC Complement Altern Med. 2015 Apr 10;15:113. doi: 10.1186/s12906-015-0639-y.

The resveratrol oligomers, cis- and trans-gnetin H, from Paeonia suffruticosa seeds inhibit the growth of several human cancer cell lines. Gao Y1, He C2, Ran R3, Zhang D4, Li D5, Xiao PG6, Altman E7. J Ethnopharmacol. 2015 Apr 9. pii: S0378-8741(15)00233-0. doi: 10.1016/j.jep.2015.03.074. [Epub ahead of print]


Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. Laccetti AL1, Pruitt SL1, Xuan L1, Halm EA1, Gerber DE2. J Natl Cancer Inst. 2015 Feb 9;107(4). pii: djv002. doi: 10.1093/jnci/djv002. Print 2015 Apr.

Tumor board participation among physicians caring for patients with lung or colorectal cancer. Kehl KL1, Landrum MB1, Kahn KL1, et al. J Oncol Pract. 2015 May;11(3):e267-78. doi: 10.1200/JOP.2015.003673. Epub 2015 Apr 28.

Does a Recent Cancer Diagnosis Predict Smoking Cessation? An Analysis From a Large Prospective US Cohort. Westmaas JL1, Newton CC2, Stevens VL2, et al. J Clin Oncol. 2015 Apr 20. pii: JCO.2014.58.3088. [Epub ahead of print]

The effect of modality and narration style on recall of online health information: results from a web-based experiment. Bol N1, van Weert JC, de Haes HC, Loos EF, Smets EM. J Med Internet Res. 2015 Apr 24;17(4):e104. doi: 10.2196/jmir.4164.

Hormone Use, Reproductive History and Risk of Lung Cancer: The Women’s Health Initiative Studies. Schwartz AG1, Ray RM, Cote ML, et al. J Thorac Oncol. 2015 Apr 3. [Epub ahead of print]

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)